PA
ATXS

Profund Advisors’s Astria Therapeutics ATXS Stock Holding History

Profund Advisors’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-11,038
Closed -$122K – 1108
2024
Q3 		$122K Sell
11,038
-9,361
-46% -$104K ﹤0.01% 1096
2024
Q2 		$186K Sell
20,399
-4,397
-18% -$42.9K 0.01% 1000
2024
Q1 		$349K Buy
+24,796
New +$309K 0.01% 772

Other funds holding ATXS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Profund Advisors's ATXS Position: Q4 2024 in Review

Profund Advisors sold out of Astria Therapeutics (ATXS) in Q4 2024, closing a stake of 11,038 shares — an estimated $122K sold.

Profund Advisors first reported a position in ATXS in Q1 2024 and held it in 3 quarters. The position peaked at $349K in Q1 2024. 110 funds tracked by Wall St. Rank hold ATXS as of Q4 2024.

  • Profund Advisors reported no remaining Astria Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Profund Advisors sold 11,038 Astria Therapeutics shares in Q4 2024, an estimated $122K.
  • Profund Advisors first reported a position in Astria Therapeutics in Q1 2024 and held it in 3 quarters.
  • Profund Advisors's Astria Therapeutics position peaked at $349K in Q1 2024.
  • 110 funds tracked by Wall St. Rank held Astria Therapeutics as of Q4 2024.

Based on Profund Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.